Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 07, 2015 4:26 AM ET

Biotechnology

Company Overview of ViaCyte, Inc.

Company Overview

ViaCyte, Inc., a preclinical stage stem cell engineering company, develops and commercializes cell therapies to treat diabetes in the United States and internationally. The company develops human embryonic stem cells for Type 1 and Type 2 diabetic patients, as well as therapies based on pancreatic beta cell progenitors derived from human pluripotent stem cells. It develops insulin-producing cells from human embryonic stem cells to produce islet cells; and Encaptra, a vascularizing device that enables implanted pancreatic progenitor cells to survive and differentiate into functioning islet cells. The company was formerly known as Novocell, Inc. and changed its name to ViaCyte, Inc. in May 201...

3550 General Atomics Court

San Diego, CA 92121

United States

Founded in 1999

Phone:

858-455-3708

Fax:

858-455-3962

Key Executives for ViaCyte, Inc.

Chief Executive Officer and President
Age: 58
Vice President of Finance and Corporate Controller
Chief Medical Officer and Vice President of Clinical Development
Age: 60
Senior Vice President of Science & Technology
Chief Development Officer and Vice President of Device Research & Development
Compensation as of Fiscal Year 2014.

ViaCyte, Inc. Key Developments

ViaCyte, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:20 AM

ViaCyte, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:20 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

ViaCyte, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 10:35 AM

ViaCyte, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 10:35 AM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Paul K. Laikind, Chief Executive Officer and President.

ViaCyte, Inc. Receives Clearance from Health Canada for Diabetes Clinical Trial

ViaCyte, Inc. received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the company's Phase 1/2 clinical trial of its VC-01TM product candidate. The VC-01 product candidate is currently being evaluated in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. The location and enrollment start date of the first Canadian clinical trial site have not yet been disclosed. The Investigational New Drug application for the Phase 1/2 trial, called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was allowed by the US Food and Drug Administration in August 2014. The STEP ONE trial was launched in September 2014 at UC San Diego Health System, with the support of the UC San Diego Sanford Stem Cell Clinical Center and under the direction of Principal Investigator Robert Henry, MD. The first implant was performed in October 2014. In addition to determining the safety of the product candidate in these patients, STEP ONE is designed to evaluate the effectiveness of the VC-01 product candidate in replacing the lost endocrine function that is central to the disease. In an open-label, dose-escalating format, ViaCyte expects to enroll approximately 40 patients in the study at multiple clinical sites.

Similar Private Companies By Industry

Company Name Region
Rhodia Pharma Solutions, Inc United States
EpiCypher, Inc. United States
Nucleico, LLC United States
Protiveris Inc. United States
Cantata Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 8, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ViaCyte, Inc., please visit viacyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.